Issues
-
Cover Image
Cover Image
ZIKVBR displays strong and specific oncolytic property against human central nervous system (CNS) embryonal tumors. Tumor cells infected with the virus (red) are readily destroyed and are ineffective in producing new functional viral particles. In tumor-bearing mice, ZIKVBR induces significant CNS tumor remission and spinal cord metastasis inhibition. Neural stem-like cancer cells with high Wnt/β-catenin basal activity are more susceptible to the oncolytic effects of ZIKVBR. For details, see article by Kaid and colleagues on page 3363. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Research
Table of Contents
Breaking Insights
Review
Genome and Epigenome
Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases
Network Modeling of microRNA–mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN
SETD2 Haploinsufficiency for Microtubule Methylation Is an Early Driver of Genomic Instability in Renal Cell Carcinoma
Molecular Cell Biology
Silencing of Long Noncoding RNA MIR22HG Triggers Cell Survival/Death Signaling via Oncogenes YBX1, MET, and p21 in Lung Cancer
Tumor Biology and Immunology
Blockade of Myeloid-Derived Suppressor Cell Expansion with All-Trans Retinoic Acid Increases the Efficacy of Antiangiogenic Therapy
Sustained Adrenergic Signaling Promotes Intratumoral Innervation through BDNF Induction
CD163 Is Required for Protumoral Activation of Macrophages in Human and Murine Sarcoma
Translational Science
Rho Kinase Inhibition by AT13148 Blocks Pancreatic Ductal Adenocarcinoma Invasion and Tumor Growth
Adoptive Immunotherapy Using PRAME-Specific T Cells in Medulloblastoma
Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors
Zika Virus Selectively Kills Aggressive Human Embryonal CNS Tumor Cells In Vitro and In Vivo
Convergence and Technologies
Population and Prevention Science
Retractions
Corrections
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.